Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Director dealing

2 Jan 2020 16:50

RNS Number : 6117Y
Polarean Imaging PLC
02 January 2020
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Director Dealing

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 31 December 2019 that Mr Richard Hullihen, the Company's CEO, has purchased a total of 347,100 ordinary shares of £0.00037 ("Ordinary Shares") via three transactions which are summarised in the table below (the "Transactions").

Date of Transaction

Number of Ordinary Shares purchased

Price per Ordinary Share

13 December 2019

100,000

20.22p

16 December 2019

100,000

20.02p

27 December 2019

147,100

23.87p

 

Following this Transactions, Mr Hullihen holds a beneficial interest in 2,928,899 Ordinary Shares, representing 2.56 per cent. of the Company's issued share capital with voting rights.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Soltan Tagiev (Corporate Finance) 

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Mr Richard Hullihen

2.

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Polarean Imaging Plc

b)

LEI:

213800DGR2BHXJ36OL37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

 

Ordinary shares of £0.00037

GB00BF3DT583

b)

Nature of the transaction:

Purchase of shares

c)

Price(s) and volume(s):

 

Transaction

Price(s)

Volume(s)

(i)

(ii)

(iii)

20.22 pence

20.02 pence

23.87 pence

100,000

100,000

147,100

 

d)

Aggregated information:

Aggregated volume:

Price:

Single transaction as in 4 c) above

Price(s)

Volume(s)

See above

347,100

 

 

 

e)

Date of the transactions:

(i): 13 December 2019

(ii): 16 December 2019

(iii): 27 December 2019

f)

Place of the transactions:

London Stock Exchange, AIM Market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDZGGMVZNGGZM
Date   Source Headline
15th Feb 20237:00 amRNSInvestor presentation
13th Feb 20232:05 pmRNSSecond Price Monitoring Extn
13th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 202311:05 amRNSSecond Price Monitoring Extn
13th Feb 202311:00 amRNSPrice Monitoring Extension
13th Feb 20239:05 amRNSSecond Price Monitoring Extn
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Feb 20237:00 amRNSCompany Update
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20234:25 pmRNSFDA grants New Chemical Entity designation
27th Jan 20237:00 amRNSBlock listing six monthly return
28th Dec 20229:05 amRNSSecond Price Monitoring Extn
28th Dec 20229:00 amRNSPrice Monitoring Extension
28th Dec 20227:00 amRNSFDA Approves XENOVIEW™ (Xe 129 hyperpolarized)
3rd Oct 202211:05 amRNSSecond Price Monitoring Extn
3rd Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSUpdate on New Drug Application
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 202211:06 amRNSSecond Price Monitoring Extn
22nd Sep 202211:00 amRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:04 amRNSUpdate on New Drug Application
31st Aug 20227:00 amRNSHalf-year Report
26th Aug 20227:00 amRNSDirectorate appointment
4th Aug 20224:40 pmRNSSecond Price Monitoring Extn
4th Aug 20224:35 pmRNSPrice Monitoring Extension
28th Jul 20227:00 amRNSTotal voting rights and block listing return
8th Jul 20227:00 amRNSSystem delivery
29th Jun 20224:35 pmRNSResult of AGM
18th May 20227:00 amRNSFinal Results
11th May 20227:00 amRNSNotice of Results
11th May 20227:00 amRNSOxford research collaboration in long COVID
5th May 20227:00 amRNSDirectorate Change
29th Apr 20227:00 amRNSTotal Voting Rights
25th Apr 20227:00 amRNSNew system order
20th Apr 20227:00 amRNSNew Drug Application Resubmission update
14th Apr 20227:00 amRNSAppointment of Non-Executive Director
8th Apr 20227:00 amRNSExercise of Options and Total Voting Rights
31st Mar 20222:05 pmRNSSecond Price Monitoring Extn
31st Mar 20222:00 pmRNSPrice Monitoring Extension
31st Mar 202211:06 amRNSSecond Price Monitoring Extn
31st Mar 202211:00 amRNSPrice Monitoring Extension
31st Mar 20229:00 amRNSPrice Monitoring Extension
31st Mar 20227:00 amRNSNew Drug Application Resubmission
25th Feb 20227:00 amRNSTotal Voting Rights
14th Feb 20227:00 amRNSNew system order
28th Jan 20227:01 amRNSBlock Listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.